719 Stock Overview
About the company
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand. It also provides prepared Chinese herbal medicine decoction, traditional Chinese medicines, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc.; and chemical raw materials, such as dimethyl sulfate, isobutylbenzene, 1,8-diazabicyclo, undec-7-ene, and tetramethylguanidine. In addition, the company offers materials and intermediates, powders for injection and tablets; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; and health products research and development activities. Further, it engages in the certification business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as the sale of mechanical, hardware, and electrical equipment. Additionally, the company produces and sells high-end steroid system APIs and intermediates; and provides internet data, internet sells, and internet information services for pharmaceuticals and medical devices, etc. It operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
Snowflake Analysis
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Shandong Xinhua Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.46 |
| 52 Week High | HK$17.00 |
| 52 Week Low | HK$3.65 |
| Beta | 0.095 |
| 1 Month Change | -10.03% |
| 3 Month Change | -36.29% |
| 1 Year Change | 57.95% |
| 3 Year Change | 50.23% |
| 5 Year Change | 4.98% |
| Change since IPO | 216.91% |
Recent News & Updates
Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07
Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18Recent updates
Shandong Xinhua Pharmaceutical (HKG:719) Takes On Some Risk With Its Use Of Debt
Mar 07Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 18These 4 Measures Indicate That Shandong Xinhua Pharmaceutical (HKG:719) Is Using Debt Extensively
Jul 27Shandong Xinhua Pharmaceutical (HKG:719) Has Affirmed Its Dividend Of HK$0.18
Jul 04Estimating The Intrinsic Value Of Shandong Xinhua Pharmaceutical Company Limited (HKG:719)
Mar 09We Think Shandong Xinhua Pharmaceutical (HKG:719) Can Stay On Top Of Its Debt
Dec 21Does Shandong Xinhua Pharmaceutical (HKG:719) Deserve A Spot On Your Watchlist?
Apr 06What Kind Of Shareholders Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719)?
Mar 19Is Shandong Xinhua Pharmaceutical (HKG:719) A Risky Investment?
Feb 26Are Shandong Xinhua Pharmaceutical's (HKG:719) Statutory Earnings A Good Guide To Its Underlying Profitability?
Feb 05
Shandong Xinhua Pharmaceutical (HKG:719) Share Prices Have Dropped 43% In The Last Three Years
Jan 18Is Shandong Xinhua Pharmaceutical Company Limited (HKG:719) A Smart Pick For Income Investors?
Dec 29Do Institutions Own Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares?
Dec 14Is Shandong Xinhua Pharmaceutical (HKG:719) Using Too Much Debt?
Nov 26Shareholder Returns
| 719 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 3.2% | -0.3% | 3.5% |
| 1Y | 57.9% | -13.1% | -6.9% |
Return vs Industry: 719 exceeded the Hong Kong Pharmaceuticals industry which returned -13.1% over the past year.
Return vs Market: 719 exceeded the Hong Kong Market which returned -7% over the past year.
Price Volatility
| 719 volatility | |
|---|---|
| 719 Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in HK Market | 13.8% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 719 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: 719's weekly volatility has decreased from 16% to 11% over the past year, but is still higher than 75% of Hong Kong stocks.
Shandong Xinhua Pharmaceutical Company Limited Fundamentals Summary
| 719 fundamental statistics | |
|---|---|
| Market Cap | HK$15.53b |
| Earnings (TTM) | HK$410.34m |
| Revenue (TTM) | HK$8.14b |
10.6x
P/E Ratio0.5x
P/S RatioIs 719 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 719 income statement (TTM) | |
|---|---|
| Revenue | CN¥7.07b |
| Cost of Revenue | CN¥5.30b |
| Gross Profit | CN¥1.77b |
| Other Expenses | CN¥1.41b |
| Earnings | CN¥356.66m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Mar 24, 2023
| Earnings per share (EPS) | 0.53 |
| Gross Margin | 25.02% |
| Net Profit Margin | 5.04% |
| Debt/Equity Ratio | 22.9% |
How did 719 perform over the long term?
See historical performance and comparison